Blockade of angiotensin II type 1 (AT 1 ) receptor improves insulin sensitivity and diabetic condition. In short-term regulation, angiotensin II changes lipid metabolism and in long-term regulation, it affects insulin sensitivity and adipocyte differentiation in adipose tissue. These effects are mainly mediated by AT 1 receptor. AT 1 receptor blocker improves insulin sensitivity and induces adipocyte differentiation by increasing peroxisome proliferator-activated receptor-c (PPARc) and transcription factors in adipose tissue in diabetic and atherosclerotic models. Clinical studies indicate that AT 1 receptor blockers prevent the new onset of diabetes and improve insulin sensitivity. On the other hand, AT 2 receptor stimulation appears to cause antagonistic actions against AT 1 receptor signaling. Although further investigations are necessary on the AT 2 receptor function in adipose tissue, studies using AT 2 receptor agonists, in addition to those using AT 1 receptor blockers, would contribute to the treatment of metabolic syndrome and associated pathological disorders. 
INTRODUCTION
Renin-angiotensin system (RAS) is well known as an important regulator of blood pressure. Recent studies indicate the involvement of RAS in metabolic dysfunction. Clinical reports have shown that angiotensin II type 1 (AT 1 ) receptor blocker (ARB) and angiotensinconverting enzyme inhibitor decrease the onset of diabetes. 1 Moreover, there are recent reports that the activation of RAS induces insulin resistance through AT 1 receptor-mediated signaling based on recent clinical and experimental data. 2 Recently, accumulating data have been reported about the pivotal roles of angiotensin II in adipose tissue function and angiotensin II receptors. Therefore, in this review, we will summarize and discuss the roles of RAS in adipose tissue focusing on AT 1 and AT 2 receptors.
RAS AND INSULIN RESISTANCE
Earlier studies have shown that angiotensin II induces insulin resistance. Blockade of AT 1 receptor improved oral glucose tolerance test without a significant change in plasma insulin concentration in diabetic model mice. 3, 4 It suggests that AT 1 receptor blockade improves glucose intolerance in diabetic conditions. Similar effects were observed in other models of diabetes and glucose intolerance. [5] [6] [7] This effect of AT 1 receptor blockade on glucose intolerance was not caused by the change in insulin secretion. However, the glucose uptake in insulin-sensitive tissues is increased by ARBs especially in skeletal muscles. 3 The increase in glucose uptake was observed in insulinsensitive organs, such as skeletal muscle and white adipose tissue, at least partly because of the activation of the insulin-mediated IRS1/PI3/ GLUT4 cascade and the increase in blood flow. 3, 4, 8, 9 By contrast, we reported that in AT 2 receptor null mice, glucose uptake in adipose tissues was increased. Moreover, it has been reported that ARB could protect the pancreas in type II diabetic animal model with enhanced insulin secretion. 10 In the following parts, we will review mainly the roles of angiotensin II receptor subtype in adipose tissue.
RAS COMPONENTS IN ADIPOSE TISSUE
White adipose tissue acts not only as a reservoir of exceeded fuel but also as an endocrine organ secreting various bioactive factors. 11, 12 However, Massiéra et al. 13 have reported that angiotensinogen production in adipose tissue plays an important role of RAS in whole body. Using gene-engineered mice, they indicate that adipose tissue produces angiotensinogen and it may be an important source of plasma angiotensinogen as well as the liver. The angiotensinogendeficient mice were hypotensive and showed neither detectable angiotensinogen in plasma nor morphological changes in the kidney. However, these changes observed in angiotensinogen-deficient mice were almost restored in mice, in which angiotensinogen expression is restricted to adipose tissue. 13 As adipose tissues express AT 1 and AT 2 receptors, it is possible that RAS in adipose tissue acts as a local regulator of adipose tissue function. In our study, AT 1 receptor is a major subtype, and the expression of AT 2 receptor is approximately 1% of AT 1 receptor expression in adipose tissue. 14 However, it is reported that AT 2 receptor expression is elevated after induction of adipocyte differentiation. 15 Moreover, earlier reports suggest that AT 2 receptor is, at least, expressed in adipose tissue or adipocytes with some functions. 16 
METABOLIC ACTION OF ANGIOTENSIN II ON ADIPOSE TISSUE
Modulation of angiotensin II receptors affects plasma lipid concentration. Treatment of mice with ARB decreased the plasma level of cholesterol and free fatty acids, 14, 17 which is closely related with metabolic syndrome and insulin resistance.
A major type of adipose tissue in human beings is white adipose tissue. In the classical aspect of adipose tissue, white adipocytes are enlarged by the accumulation of lipids and induce obesity. In the acute phase, the lipid content in white adipose tissue is regulated by the balance of lipid synthesis and breakdown. Lipid synthesis in white adipose tissue is regulated by insulin. Lipid breakdown is regulated by humoral and neural stimulation similar to sympathetic nerve activity. Lipid breakdown in white adipose tissue also depends on the energy expenditure in the whole body.
Angiotensin II is involved in metabolic changes in adipocytes. In an earlier report, angiotensin II induced lipolysis in white adipose tissue. 18 It is also reported that the mice lacking angiotensin-converting enzyme increased energy expenditure, reduced fat mass and improved glucose clearance. 19 In addition, blockade of AT 1 receptor increased glucose uptake in white adipose tissue. 4 The modulation of insulin signaling and the regulation of oxidative stress are involved in the metabolic action of angiotensin II in adipose tissue. 4, 17 These effects of angiotensin II are observed in short-term (or acute) regulation of metabolism. However, the regulation of the total adipose tissue mass depends not only on acute metabolic changes but also on various other factors.
ANGIOTENSIN II AND ADIPOCYTE DIFFERENTIATION
Recent studies suggest a possible regulation of white adipose tissue mass by modulating adipocyte differentiation. 20, 21 Studies of action of agonist for peroxisome proliferator-activated receptor-g (PPARg: a transcription factor) suggest that the activation of PPARg induces adipocyte differentiation, thereby inducing smaller size adipocytes and increasing insulin sensitivity in white adipocytes. 21 By contrast, the reduction of PPARg activity suppresses adipocyte differentiation and induces enlargement of white adipocytes. Earlier studies suggest that the small-sized adipocytes increase their insulin sensitivity.
Earlier studies indicate that a blockade of the AT 1 receptor enhances adipocyte differentiation. Moreover, it has been suggested that AT 1 receptor blockade and AT 2 receptor stimulation increases differentiation from mesenchymal stem cell in vitro. 22 In our earllier report, we showed that the deficiency of AT 1 a receptor, a major subclass of AT 1 receptor, increased the adipocyte differentiation and the number of small-sized adipocytes in atherosclerotic model mice. 17 The role of another subtype of AT 1 receptor, AT 1 b receptor, is totally unknown. Apolipoprotein E-deficient (ApoE-knockout (KO)) mice are widely used as an animal model of atherosclerosis. ApoEKO mice showed an enlargement of adipocyte size. 17 In their adipose tissue, the expression of adiponectin and PPARg was lower than that of wild-type mice. These changes in ApoEKO mice were recovered by the deletion of AT 1 a receptor (AT 1 a/ApoE double KO mice). Furuhashi et al. 23 reported that an ARB, olmesartan, decreased adipocyte size without a change in the epididymal fat pads, accompanied by the improvement of insulin sensitivity in fructose-fed rats. Moreover, adiponectin is produced by adipose tissue and is involved in adipose tissue metabolism and insulin sensitivity. 24 Our earlier results have indicated that the expression of adiponectin and adipocyte differentiation factors, such as C/EBPa and aP2, was increased in AT 1 a/ApoE double KO mice or with an ARB. 17 
ROLES OF AT 2 RECEPTOR IN ADIPOSE TISSUE DYSFUNCTION
The expression of AT 2 receptor in white adipose tissue is not abundant. Although the expression in adipose tissue seems to be low, AT 2 receptor stimulation affects the adipose tissue function. It is reported that AT 2 receptor-deficient mice prevented adipose tissue depletion during fasting. 25 The role of AT 2 receptor stimulation in adipose tissue function is still controversial. 15 Administration of insulin increases glucose uptake in wild-type mice. This effect of insulin was lower in AT 2 receptor KO mice, suggesting that the lack of AT 2 receptor stimulation reduces insulin sensitivity in adipose tissue. The role of AT 2 receptor stimulation in adipose tissue function is still controversial. Yvan-Charvet et al. 16 reported that the deletion of the AT 2 receptor reduced the adipose cell size and protected from dietinduced obesity and insulin resistance. However, in our experiment using atherosclerotic ApoEKO mice with AT 2 receptor deficiency (AT 2 /ApoE double KO mice), the lack of AT 2 receptor decreased the expression of adipocyte differentiation factors, such as PPARg, C/EBP and aP2, in white adipose tissue after treatment with high cholesterol diet. 14 In these mice, adipocyte size and tissue mass were enlarged. In addition, plasma cholesterol and free fatty acid levels were higher in AT 2 /ApoE double-KO mice. In Figure 1 , we have summarized the possible roles of AT 1 and AT 2 receptors in adipose tissue.
CLINICAL ASPECTS OF RAS IN ADIPOSE TISSUE
It has been reported that the risk of atherosclerosis is higher in diabetic patients than in non-diabetic individuals. The metabolic syndrome is typically characterized by obesity associated with hypertension, hyperlipidemia and hyperglycemia and dysregulated adipose tissue function, and appears to be an important factor in the exaggeration of metabolic syndrome and the pathogenesis of vascular diseases. The prevention of metabolic syndrome becomes highlighted in the field of diabetes and cardiovascular medicine.
Recent clinical studies have shown that ARBs prevent the new onset of diabetes and improve insulin sensitivity. 1,2,26, 27 The results of clinical studies also suggest that blockade of the AT 1 receptor decreases events related to atherosclerosis. 28, 29 These results support the notion that AT 1 receptor stimulation is pivotal in the pathogenesis of the metabolic syndrome and associated vascular lesion formation. Moreover, the studies on the roles of AT 2 receptor suggest that AT 2 receptor agonists, such as compound 21, could be useful and would contribute to the treatment of metabolic syndrome and associated pathological disorders. 30 
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